Hospital
Mainehealth
Mainehealth was paid $5.33M by Medicaid between Jan 2018 and Dec 2024, across 371 billing codes. Its largest line is 99284, emergency room visit (serious) — 8.7% of everything it billed.
33Billing provider infoMAINEHEALTH
BELFAST, ME 04915
BELFAST, ME 04915
33aNPI1841397932assigned 09/20/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$5.33M
24GClaims936,042
24DCodes billed371
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HUNTER, ROBERT controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,568 | $697K | |
| 2019 | 120,492 | $772K | |
| 2020 | 110,474 | $604K | |
| 2021 | 138,789 | $626K | |
| 2022 | 150,341 | $799K | |
| 2023 | 160,222 | $973K | |
| 2024incomplete | 154,156 | $859K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 29,957 | 18,453 | $464K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.5% | 2,792 | 2,624 | $455K |
| G0378 | Hospital observation service, per hour | 5.8% | 2,194 | 1,891 | $310K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 11,795 | 7,036 | $305K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.5% | 45,386 | 34,362 | $293K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.6% | 3,667 | 1,965 | $248K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 2,507 | 2,334 | $185K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.4% | 33,038 | 28,781 | $183K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.9% | 22,396 | 16,115 | $152K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.8% | 42,422 | 33,727 | $147K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 1,093 | 1,050 | $145K |
| 71046 | Radiologic examination, chest; 2 views | 2.4% | 5,729 | 5,404 | $126K |
359 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 38,209 | $119K |
| 71250 | 2.1% | 862 | $111K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 20,249 | $96K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.7% | 1,726 | $92K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 5,172 | $92K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 12,390 | $80K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 15,356 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 6,556 | $64K |
| 80053 | Comprehensive metabolic panel | 1.1% | 33,052 | $57K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.1% | 556 | $57K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 12,102 | $57K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,369 | $45K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,035 | $43K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,822 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,694 | $38K |
| 73030 | <1% | 1,570 | $36K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,102 | $35K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 117 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,448 | $32K |
| 97161 | <1% | 3,455 | $31K | |
| 73502 | <1% | 1,074 | $29K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,546 | $28K |
| 73630 | <1% | 1,848 | $27K | |
| 94762 | <1% | 905 | $27K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,017 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,292 | $25K |
| 76376 | <1% | 1,383 | $24K | |
| 94729 | <1% | 1,822 | $24K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 206 | $23K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 153 | $23K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,771 | $23K |
| 72100 | <1% | 914 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,263 | $20K |
| 73562 | <1% | 853 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,134 | $18K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 4,629 | $18K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,067 | $18K |
| 94726 | <1% | 1,464 | $17K | |
| 73610 | <1% | 1,336 | $16K | |
| 93017 | <1% | 260 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 299 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,031 | $15K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,333 | $14K |
| 84484 | <1% | 7,414 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,109 | $12K |
| 83880 | <1% | 3,074 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,774 | $12K |
| 94060 | <1% | 767 | $11K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,765 | $11K |
| 76642 | <1% | 400 | $11K | |
| 82043 | <1% | 2,055 | $10K | |
| 96376 | <1% | 1,125 | $10K | |
| 73130 | <1% | 884 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,030 | $10K |
| 92557 | <1% | 528 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 79 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,671 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,830 | $9K |
| 20610 | <1% | 689 | $9K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 1,306 | $9K |
| 73560 | <1% | 580 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 532 | $9K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 273 | $9K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,394 | $9K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,046 | $9K |
| 86140 | <1% | 4,368 | $9K | |
| 85610 | <1% | 8,921 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,982 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,698 | $8K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 39,806 | $8K |
| 98929 | <1% | 1,601 | $8K | |
| 93971 | <1% | 237 | $8K | |
| 83735 | <1% | 8,306 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 985 | $8K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 170 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,730 | $7K |
| 99442 | <1% | 830 | $7K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 69,277 | $7K |
| 82728 | <1% | 2,594 | $6K | |
| 73110 | <1% | 663 | $6K | |
| 93242 | <1% | 220 | $6K | |
| 90715 | <1% | 1,619 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,558 | $5K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 755 | $5K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 11,341 | $5K |
| 87040 | <1% | 2,271 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,162 | $5K |
| 99443 | <1% | 363 | $5K | |
| 90960 | End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits | <1% | 231 | $5K |
| 82607 | <1% | 2,388 | $5K | |
| 83550 | <1% | 2,080 | $5K | |
| 99205 | Prolong outpt/office vis | <1% | 535 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,414 | $5K |
| 94010 | <1% | 615 | $5K | |
| 92567 | <1% | 957 | $5K | |
| 97165 | <1% | 973 | $4K | |
| J3490 | Unclassified drugs | <1% | 176 | $4K |
| 83540 | <1% | 2,166 | $4K | |
| V2632 | Posterior chamber intraocular lens | <1% | 154 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,817 | $4K |
| 82746 | <1% | 1,288 | $4K | |
| 00142 | <1% | 141 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 576 | $4K |
| 85027 | <1% | 6,542 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,537 | $4K |
| 82948 | <1% | 7,894 | $4K | |
| 11719 | <1% | 676 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 43 | $3K |
| 96415 | <1% | 101 | $3K | |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | <1% | 132 | $3K |
| 97116 | <1% | 2,811 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,545 | $3K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,668 | $3K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,660 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,834 | $3K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 43 | $3K |
| 87186 | <1% | 2,626 | $3K | |
| 80061 | Lipid panel | <1% | 8,247 | $3K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 434 | $3K |
| 85651 | <1% | 2,158 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,181 | $2K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,800 | $2K |
| 99219 | <1% | 528 | $2K | |
| 87070 | <1% | 3,487 | $2K | |
| 81001 | <1% | 7,193 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 991 | $2K |
| 96367 | <1% | 208 | $2K | |
| 83605 | <1% | 3,058 | $2K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,364 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,141 | $2K |
| 99441 | <1% | 372 | $2K | |
| 74018 | <1% | 192 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,034 | $2K |
| 83690 | <1% | 4,134 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 773 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 776 | $2K |
| 93798 | <1% | 63 | $2K | |
| 84439 | <1% | 933 | $2K | |
| 86803 | <1% | 2,011 | $2K | |
| 82805 | <1% | 525 | $2K | |
| 81002 | <1% | 4,360 | $2K | |
| 83037 | <1% | 2,826 | $2K | |
| 76536 | <1% | 53 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 862 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 350 | $2K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 87 | $1K |
| 93225 | <1% | 59 | $1K | |
| 83970 | <1% | 267 | $1K | |
| 80069 | <1% | 244 | $1K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 16 | $1K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 362 | $1K |
| 90961 | <1% | 107 | $1K | |
| 00811 | <1% | 104 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 257 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 813 | $1K |
| 87481 | <1% | 1,268 | $1K | |
| 98926 | <1% | 397 | $1K | |
| 86850 | <1% | 1,578 | $1K | |
| 97166 | <1% | 299 | $1K | |
| 10060 | <1% | 83 | $1K | |
| 85018 | <1% | 1,456 | $1K | |
| 87077 | <1% | 2,769 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 564 | $997.44 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 102 | $985.48 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,120 | $980.43 |
| 85379 | <1% | 1,420 | $956.67 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 313 | $945.91 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 378 | $891.65 |
| 29581 | <1% | 88 | $875.94 | |
| 93356 | <1% | 308 | $869.93 | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 49 | $831.69 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 166 | $814.42 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 50 | $812.40 |
| 86618 | <1% | 2,066 | $771.97 | |
| 82570 | <1% | 1,023 | $746.19 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 751 | $740.72 |
| 87469 | <1% | 758 | $737.49 | |
| 87468 | <1% | 758 | $737.41 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 25 | $729.90 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,465 | $720.28 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 294 | $718.99 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,584 | $643.35 |
| 80305 | <1% | 2,837 | $637.72 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 268 | $617.45 |
| 85014 | <1% | 809 | $605.58 | |
| 77065 | Tomosynthesis, mammo | <1% | 68 | $603.93 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 761 | $595.79 |
| 90662 | <1% | 856 | $594.03 | |
| 93246 | <1% | 24 | $591.69 | |
| 87511 | <1% | 677 | $576.77 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,519 | $529.13 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,042 | $524.86 |
| 82784 | <1% | 190 | $500.32 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,077 | $499.69 |
| 97162 | <1% | 67 | $498.09 | |
| 85652 | <1% | 899 | $487.95 | |
| 84156 | <1% | 714 | $481.20 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 56 | $473.14 |
| 71271 | <1% | 203 | $470.88 | |
| G0008 | Administration of influenza virus vaccine | <1% | 3,297 | $456.48 |
| 95251 | <1% | 137 | $451.37 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 40 | $442.75 |
| 31575 | <1% | 30 | $440.23 | |
| 86900 | <1% | 1,588 | $425.32 | |
| 93226 | <1% | 24 | $409.68 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,595 | $403.93 |
| 85730 | <1% | 527 | $399.49 | |
| 12001 | <1% | 97 | $387.29 | |
| 81003 | <1% | 2,998 | $381.38 | |
| 86901 | <1% | 1,625 | $379.83 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 105 | $376.38 |
| 87205 | <1% | 863 | $373.67 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 323 | $372.76 |
| 95806 | <1% | 12 | $369.91 | |
| 84703 | <1% | 2,841 | $366.42 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,061 | $362.76 |
| 84550 | <1% | 733 | $350.35 | |
| 91322 | <1% | 232 | $350.05 | |
| 98927 | <1% | 148 | $346.05 | |
| 97113 | <1% | 175 | $341.54 | |
| 73564 | <1% | 13 | $341.48 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 14 | $340.23 |
| 72050 | <1% | 25 | $322.79 | |
| 82803 | <1% | 204 | $301.92 | |
| 36600 | <1% | 31 | $294.06 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 69 | $258.43 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 56 | $250.74 |
| 36591 | <1% | 20 | $237.17 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,681 | $234.31 |
| 90480 | <1% | 451 | $233.78 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,056 | $224.27 |
| 88342 | <1% | 14 | $206.99 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,509 | $203.96 |
| 99223 | Prolong inpt eval add15 m | <1% | 53 | $203.62 |
| 87340 | <1% | 611 | $199.77 | |
| 91320 | <1% | 139 | $195.87 | |
| 99217 | <1% | 97 | $191.92 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 44 | $184.54 |
| 0064A | <1% | 591 | $181.83 | |
| 83615 | <1% | 204 | $180.92 | |
| 84100 | <1% | 469 | $177.84 | |
| 36416 | <1% | 161 | $177.57 | |
| 93016 | <1% | 159 | $176.63 | |
| 96368 | <1% | 14 | $168.86 | |
| 20553 | <1% | 34 | $168.09 | |
| 90670 | <1% | 295 | $160.88 | |
| 88142 | <1% | 910 | $158.03 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 219 | $142.67 |
| 73140 | <1% | 16 | $137.17 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $127.07 |
| 87484 | <1% | 124 | $123.48 | |
| 99220 | <1% | 31 | $123.15 | |
| 92523 | <1% | 620 | $120.65 | |
| 84702 | <1% | 484 | $119.56 | |
| 93018 | <1% | 158 | $119.32 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 51 | $117.26 |
| 92610 | <1% | 41 | $114.00 | |
| 81025 | <1% | 874 | $112.70 | |
| 87522 | Neg quan hep c or qual rna | <1% | 42 | $110.67 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 94 | $108.28 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 52 | $106.35 |
| 88304 | <1% | 28 | $103.19 | |
| 0134A | <1% | 283 | $101.58 | |
| 74022 | <1% | 12 | $101.20 | |
| 84165 | <1% | 42 | $101.03 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,789 | $100.51 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 334 | $99.32 |
| 98968 | <1% | 64 | $91.20 | |
| 90686 | <1% | 1,947 | $89.67 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 224 | $86.96 |
| 99225 | <1% | 31 | $84.62 | |
| 0011A | <1% | 1,149 | $81.00 | |
| 0012A | <1% | 1,121 | $81.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $80.46 |
| 86617 | <1% | 58 | $79.12 | |
| 82550 | <1% | 102 | $76.88 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $76.78 |
| 90750 | <1% | 13 | $75.00 | |
| 94618 | <1% | 19 | $73.72 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 19 | $65.92 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,942 | $54.95 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 176 | $53.30 |
| 90677 | <1% | 13 | $48.20 | |
| 77080 | <1% | 25 | $45.87 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 25 | $44.40 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 15 | $41.42 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 26 | $36.77 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 378 | $35.16 |
| 90732 | <1% | 39 | $34.87 | |
| 86431 | <1% | 73 | $30.42 | |
| 80050 | General health panel | <1% | 56 | $29.79 |
| 83516 | <1% | 16 | $29.32 | |
| 97803 | <1% | 200 | $27.85 | |
| 86038 | <1% | 43 | $27.69 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 339 | $26.77 |
| 86780 | <1% | 702 | $26.35 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 15 | $25.82 |
| 0399T | <1% | 43 | $25.53 | |
| 93244 | <1% | 12 | $24.39 | |
| 86200 | <1% | 18 | $21.94 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 160 | $21.86 |
| 90688 | <1% | 756 | $18.00 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 27 | $17.47 |
| 76801 | <1% | 150 | $17.32 | |
| 94727 | <1% | 17 | $15.22 | |
| 82565 | <1% | 27 | $14.27 | |
| 83001 | <1% | 27 | $12.85 | |
| 83655 | <1% | 211 | $12.85 | |
| 82947 | <1% | 109 | $11.54 | |
| 0054A | <1% | 93 | $10.19 | |
| J1815 | Injection, insulin, per 5 units | <1% | 44 | $8.85 |
| 81000 | <1% | 452 | $8.69 | |
| 82040 | <1% | 29 | $8.05 | |
| 0124A | <1% | 109 | $7.78 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 22 | $6.10 |
| 87420 | <1% | 192 | $5.06 | |
| 96127 | <1% | 106 | $4.80 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 90 | $4.29 |
| 0003A | <1% | 15 | $3.59 | |
| 93227 | <1% | 25 | $2.93 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 20 | $2.75 |
| 0001A | <1% | 223 | $1.66 | |
| 90656 | <1% | 291 | $1.28 | |
| 85007 | <1% | 12 | $0.64 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 270 | $0.32 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 220 | $0.02 |
| 91303 | 0% | 181 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 475 | $0.00 |
| 91301 | 0% | 1,034 | $0.00 | |
| 0031A | 0% | 245 | $0.00 | |
| 90651 | 0% | 54 | $0.00 | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 11,528 | $0.00 |
| 82950 | 0% | 51 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 50 | $0.00 |
| 86762 | 0% | 39 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 28 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 86 | $0.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 54 | $0.00 |
| 91306 | 0% | 13 | $0.00 | |
| 97802 | 0% | 15 | $0.00 | |
| 90619 | 0% | 15 | $0.00 | |
| 0052A | 0% | 14 | $0.00 | |
| 0072A | 0% | 25 | $0.00 | |
| 97533 | 0% | 39 | $0.00 | |
| 0002A | 0% | 245 | $0.00 | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 1,041 | $0.00 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 0% | 1,763 | $0.00 |
| 99188 | 0% | 24 | $0.00 | |
| 0004A | 0% | 104 | $0.00 | |
| 0013A | 0% | 15 | $0.00 | |
| 93976 | 0% | 14 | $0.00 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 0% | 1,120 | $0.00 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 488 | $0.00 |
| 0071A | 0% | 40 | $0.00 | |
| 91300 | 0% | 434 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 26 | $0.00 |
| 90671 | 0% | 27 | $0.00 | |
| 80076 | 0% | 12 | $0.00 | |
| 90633 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNTER, ROBERT (SENIOR VICE PRESIDENT - FINANCE)
Parent organizationMAINEHEALTH
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Rockport, ME | $31.54M |
| Mainehealth | Farmington, ME | $16.71M |
| Mainehealth | Norway, ME | $10.00M |
| Mainehealth | Norway, ME | $9.84M |
| Mainehealth | Damariscotta, ME | $9.60M |
| Mainehealth | Norway, ME | $5.06M |
| Mainehealth | Livermore Falls, ME | $3.15M |
| Mainehealth | Boothbay Harbor, ME | $2.90M |
| Mainehealth | Damariscotta, ME | $2.62M |
| Mainehealth | Farmington, ME | $2.36M |
| University Pathologists | Houston, TX | $1.35M |
| Mainehealth | Farmington, ME | $435K |
| P R Hematology Oncology Group INC | Bayamon, PR | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.